The Medical Advisory Team (MAT) Vaccine Safety and Efficacy Workgroup has reviewed the relevant documents related to the Janssen Ad26.COV2.S COVID-19 vaccine as provided by the manufacturer, the U.S. Food and Drug Administration (FDA), and the U.S. Centers for Disease Control and Prevention (CDC) and concurs with the conclusions that the vaccine may prevent serious or life-threatening disease and that the known and potential benefits of the product outweigh the known and potential risks of the product. This document outlines MAT recommendations, including but not limited to:
- For those individuals who elect to receive a vaccine, approved healthcare providers in NM should administer the Janssen Ad26.COV2.S COVID-19 vaccine consistent with the Emergency Use Authorization issued by the FDA and the clinical guidance provided by the CDC.
- Approved healthcare providers in NM who administer the Janssen Ad26.COV2.S COVID-19 vaccine should ensure that each potential vaccine recipient receives the required vaccine information sheet to allow for a well-informed decision and receives the required vaccination documentation card upon vaccination.
- Approved healthcare providers and health systems should monitor on-going and updated guidance from the FDA and the CDC related to the management of vaccine supplies, which may be provided on official websites or via official email messages to pharmacies, professional associations, or state officials.